These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 28760047)

  • 1. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
    Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
    Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.
    Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW
    Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.
    Knight T; Bond TC; Popelar B; Wang L; Niewoehner JW; Anastassopoulos K; Philbin M
    Clinicoecon Outcomes Res; 2017; 9():271-279. PubMed ID: 28553129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States.
    Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ
    Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis.
    Hayes K; Panaccio MP; Goel N; Fahim M
    Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
    Askanase AD; Furie RA
    Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
    Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
    Drugs Context; 2022; 11():. PubMed ID: 35382109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.
    Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B
    Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
    Wan GJ; Niewoehner J; Hayes K
    Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 19. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Curr Med Res Opin; 2021 Mar; 37(3):431-441. PubMed ID: 33411573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.